A longitudinal analysis of radiosensitizer development in cancer therapy.
2/5 보강
TL;DR
Identifying radiosensitizers targeting multifunctional regulators, such as DDX3, may help overcome tumor heterogeneity and lead to safe, effective, and enhanced radiotherapy.
OpenAlex 토픽 ·
Effects of Radiation Exposure
Lung Cancer Research Studies
Advanced Radiotherapy Techniques
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
Identifying radiosensitizers targeting multifunctional regulators, such as DDX3, may help overcome tumor heterogeneity and lead to safe, effective, and enhanced radiotherapy.
APA
Paul T. Winnard, Venu Raman (2026). A longitudinal analysis of radiosensitizer development in cancer therapy.. Cancer letters, 645, 218373. https://doi.org/10.1016/j.canlet.2026.218373
MLA
Paul T. Winnard, et al.. "A longitudinal analysis of radiosensitizer development in cancer therapy.." Cancer letters, vol. 645, 2026, pp. 218373.
PMID
41763451 ↗
Abstract 한글 요약
It has been 75 years since the concept of a radiosensitizer was introduced as an adjuvant drug intended to enhance radiotherapy. Starting shortly after this time, we provide a brief history of how oxygen availability and hypoxia in solid tumors came to dominate the definition of a radiosensitizer and the clinical effort to deliver oxygen to patients to sensitize their tumors to radiation. Next, we review the clinical use of three classes of drugs developed based on oxygen/hypoxia criteria for radiosensitizers, as well as a fourth class that meets the original definition of a radiosensitizer as an enhancer of ionizing radiation therapy. We also present recent preclinical evaluations of potential future radiosensitizers, including our work on RK-33, a non-toxic small-molecule inhibitor of the RNA helicase DDX3. A brief presentation of advances in monitoring hypoxia and tumor blood flow is presented. Additionally, we discuss the dynamic heterogeneity of solid tumors, which has significantly contributed to many shortcomings reported in clinical trials using hypoxia-targeting radiosensitizers. From this perspective, identifying radiosensitizers targeting multifunctional regulators, such as DDX3, may help overcome tumor heterogeneity and lead to safe, effective, and enhanced radiotherapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.